

WHAT IS CLAIMED IS

1. Novel paracetamol-based, stable, liquid formulations in an aqueous solvent.

2. Novel stable, paracetamol-based, liquid formulations according to claim 1, wherein the aqueous solvent is a mixture containing water and a polyhydric compound or a water-soluble alkanol.

3. Novel stable, paracetamol-based, liquid formulations according to claim 1 ~~and claim 2~~, in an aqueous solvent, wherein the aqueous solvent is deoxygenated by bubbling a water-insoluble inert gas.

4. Novel stable, paracetamol-based, liquid formulations according to ~~anyone of claims 1 to 3~~, wherein the pH of the aqueous solvent is adjusted by means of a buffering agent, in the range of 4 to 8.

5. Novel stable, paracetamol-based, liquid formulations according to ~~anyone of claims 1 to 4~~, wherein the buffering agent yields a pH of approximately 6.0.

6. Novel stable, paracetamol-based, liquid formulations according to ~~anyone of claims 1 to 4~~, wherein the formulations further incorporate at least one free radical-scavenger.

7. Novel stable, paracetamol-based, liquid formulations according to claim 6, wherein the free radical-scavenger is chosen among ascorbic acid derivatives, organic compounds bearing at least one thiol functional group, and polyhydric compounds.

8. Novel stable, paracetamol-based, liquid formulations according to claim 6 ~~or claim 7~~, wherein the ascorbic acid derivatives are chosen from the group of D-ascorbic acid, L ascorbic acid, alkali metal ascorbates, alkaline earth metal ascorbates and ascorbic acid esters that are soluble in aqueous medium.

9. Novel stable, paracetamol-based, liquid formulations according to claim 6, wherein the organic compound bearing the thiol functional group is chosen among the compounds of the aliphatic or alicyclic series, bearing one or a number of thiol functional groups.

10. Novel stable paracetamol-based liquid formulations according to claim 6 ~~and claim 9~~, wherein the compound bearing the thiol functional group is chosen from the group of thioglycolic acid, thiolactic acid, dithiothreitol, reduced glutathion, thiourea, α -thioglycerol, cystein, acetylcystein and mercaptoethane sulfonic acid.

11. Novel stable, paracetamol-based, liquid formulations according to claim 6 ~~and claim 7~~, wherein the polyhydric compound is an aliphatic polyhydric alcohol containing from 2 to 10 carbon atoms.

12. Novel stable, paracetamol-based, liquid formulations, according to claim 6 ~~and 7~~, wherein the polyhydric compound is a sugar or a cyclic or straight chain-glucitol, having from 2 to 10 carbon atoms, selected among mannitol, sorbitol, inositol and glucose.

13. Novel stable, paracetamol-based, liquid formulations according to claim 12, wherein the polyhydric compound is glycerol.

14. Novel stable, paracetamol-based, liquid formulations according to ~~claim 1~~ ~~anyone of claims 1 to 13~~, further comprising at least one complexing agent.

15. Novel stable, paracetamol-based, liquid formulations according to
anyone of claims 1 to 14, wherein the paracetamol concentration ranges from 2
mg to 50 mg/ml as for diluted solutions.

16. Novel stable, paracetamol-based, liquid formulations according to
anyone of claims 1 to 14, wherein the paracetamol concentration ranges from
60 mg to 350 mg/ml as for concentrated solutions.

17. Novel stable, paracetamol-based, liquid formulations according to
anyone of claims 1 to 14, wherein an appropriate quantity of isotonicizing agent
is added to the preparation.

18. Novel stable, paracetamol-based, liquid formulations according to
anyone of claims 1 to 14, wherein solutions intended for parenteral
administration are sterilized by heat treatment

19. Novel stable, paracetamol-based, liquid formulations according to
anyone of claims 1 to 14, further comprising a central nervous system acting
analgesic such as for example a morphinic analgesic.

20. Novel stable, paracetamol-based, liquid formulations according to
claim 19, wherein the morphinic analgesic is a morphinic compound of natural,
semi-synthetic or synthetic origin, a phenylpiperidine compound, a nipecotic
acid compound, a phenylcyclohexanol compound or a phenylazepine
compound.

21. Novel stable, paracetamol-based, liquid formulations according to
claim 19, wherein the morphinic analgesic is present in a quantity ranging from
0,05 to 5% of paracetamol in case of morphine and from 0,2 to 2,5% in case of
codeine.

22. Novel stable, paracetamol-based, liquid formulations according to ~~anyone of claims 1 to 14~~, further comprising an anti-inflammatory agent such as that of the phenylacetic acid type.

23. Novel stable, paracetamol-based, liquid formulations according to claim 22, wherein the anti-inflammatory agent is ketoprofen.

24. Novel stable, paracetamol-based, liquid formulations according to anyone of claims 1 to 14, further comprising an antiemetic.

25. Novel stable, paracetamol-based, liquid formulations according to anyone of claims 1 to 14, further comprising an antiepileptic.

26. Novel stable, paracetamol-based, liquid formulations according to
15 anyone of claims 1 to 14, further comprising a corticosteroid.

27. Novel stable, paracetamol-based, liquid formulations according to ~~anyone of claims 1 to 14~~, further comprising a tricyclic antidepressant.